fbpx
Connect with us
  • Elysium

Dementia news

Step forward in progress of Alzheimer’s treatment

Published

on

The clinical stage pharma firm PharmaKure has been given the green light for a potentially pivotal trail of an emerging treatment for mild cognitive impairment in Alzheimer’s disease.

Regulatory body, the MHRA, has granted clinical trial authorisation for a Phase 2a study to evaluate safety and tolerability of PK051.

PK051 is an oral combined drug that targets disaggregation of amyloid-β proteins. There is increasing scientific acceptance that overproduction and/or deposition of amyloid-β is the initial event in Alzheimer’s disease pathology.

“The MHRA authorisation marks a major step forward in our mission to develop PK051 as a disease modifying therapy for MCI due to Alzheimer’s Disease,” said Dr Farid Khan, CEO, PharmaKure.

“This authorisation follows successful study results recently announced by the Company for a novel whole blood test to quantify Alzheimer’s Disease biomarkers.

“PharmaKure’s proprietary blood test can identify blood-based biomarkers in patients with Alzheimer’s Disease to provide early warning of cognitive decline.

“Used as a companion diagnostic, this could enable treatments such as PK051 to be offered earlier to provide better population-based health outcomes.”

The trial will involve 40 patients with MCI due to Alzheimer’s disease at a single site in the UK.

The first patient is expected to be dosed in early to mid 2024, with preliminary clinical data emerging within 12 months of first dose.

HIWIN

Trending